Mode
Text Size
Log in / Sign up
Phase 4 N=170 Randomized Treatment

Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section

Opioid Use · Pain, Postoperative

Enrolled (actual)
170
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcome: Primary: Pain Level — 12.3; 15.9 millimeters on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Ibuprofen (Drug); Acetaminophen (Drug); Norco (Drug)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
The University of Texas Health Science Center, Houston
Primary completion
Apr 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Level
12.3; 15.9
SECONDARY
Patient Satisfaction
2; 4; 3; 3; 11; 12

Summary

Postpartum patients delivered by cesarean section will be randomized to NSAIDS Vs NSAIDS plus opioid

Eligibility Criteria

Inclusion Criteria

  • English or Spanish speaker women who had a cesarean section

Exclusion Criteria

  • Inability or refusal to provide informed consent.
  • Reported current or prior opioid or benzodiazepine use disorder, including urine drug screen positive for a non prescribed opioid or benzodiazepine upon admission or during prenatal care.
  • Current treatment with methadone, buprenorphine or buprenorphine plus naloxone.
  • Known alcoholism disorder.
  • Severe renal or hepatic impairment.
  • Known creatinine > 1.5 at the time of delivery or severe proteinuria leading to diagnosis of renal disease prior to delivery.
  • Severe peptic ulcer disease
  • Severe asthma (if patient has asthma but has previously tolerated NSAIDS, she will be allowed to participate)
  • Known CYP450/CY92D6 mutation conferring opioid ultra-rapid metabolizer status.
  • Allergy to any of the study drugs (anaphylaxis).
  • Incarcerated or institutionalized patients.
  • Inability to follow up as outpatient in our outpatient clinic.
  • wound dehiscence or infection diagnosed prior to discharge from the hospital
  • wound vac placed prior to discharge from the hospital
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03372382). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search